S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Forecast, Price & News

$172.36
0.00 (0.00%)
(As of 09/26/2023 ET)
Compare
Today's Range
$172.36
$172.36
50-Day Range
$106.09
$172.36
52-Week Range
$21.83
$172.46
Volume
N/A
Average Volume
778,243 shs
Market Capitalization
$6.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$150.36

Reata Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.31 Rating Score
Upside/​Downside
12.8% Downside
$150.36 Price Target
Short Interest
Healthy
9.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.40mentions of Reata Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$20.83 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.02) to ($2.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

567th out of 963 stocks

Pharmaceutical Preparations Industry

255th out of 451 stocks


RETA stock logo

About Reata Pharmaceuticals (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

RETA Price History

RETA Stock News Headlines

Biogen Completes Acquisition of Reata Pharmaceuticals
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Reata Pharmaceuticals (RETA) Gets a Hold from Barclays
Biogen to Acquire Reata Pharmaceuticals
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
Expert Ratings for Reata Pharmaceuticals
See More Headlines
Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
321
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$150.36
High Stock Price Forecast
$173.00
Low Stock Price Forecast
$75.00
Forecasted Upside/Downside
-12.8%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$-311,900,000.00
Pretax Margin
-373.40%

Debt

Sales & Book Value

Annual Sales
$2.22 million
Book Value
($1.79) per share

Miscellaneous

Free Float
27,926,000
Market Cap
$6.58 billion
Optionable
Optionable
Beta
1.42

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. J. Warren Huff (Age 69)
    Chairman, CEO & Sec.
    Comp: $1.11M
  • Mr. Manmeet Singh SoniMr. Manmeet Singh Soni (Age 45)
    COO, CFO & Pres
    Comp: $1.02M
  • Mr. Michael D. WortleyMr. Michael D. Wortley (Age 75)
    Exec. VP and Chief Legal & Compliance Officer
    Comp: $773.06k
  • Dr. Colin J. Meyer M.D. (Age 44)
    Exec. VP & Chief Innovation Officer
    Comp: $842.4k
  • Ms. Dawn Carter BirMs. Dawn Carter Bir (Age 52)
    Exec. VP & Chief Commercial Officer
    Comp: $652.39k
  • Mr. Bhaskar  AnandMr. Bhaskar Anand (Age 45)
    Sr. VP & Chief Accounting Officer
  • Dr. W. Christian Wigley Ph.D.
    Sr. VP & Chief Scientific Officer
  • Mr. Steve Harman
    Sr. VP & Chief HR Officer
  • Dr. Samina Khan M.D. (Age 58)
    Chief Medical Officer & Sr. VP
  • Mr. Dakota Gallivan
    VP & Chief Healthcare Compliance Officer













RETA Stock - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RETA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RETA, but not buy additional shares or sell existing shares.
View RETA analyst ratings
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price forecast for 2023?

13 Wall Street analysts have issued 12-month target prices for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $75.00 to $173.00. On average, they predict the company's share price to reach $150.36 in the next year. This suggests that the stock has a possible downside of 12.8%.
View analysts price targets for RETA
or view top-rated stocks among Wall Street analysts.

How have RETA shares performed in 2023?

Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of 2023. Since then, RETA stock has increased by 353.7% and is now trading at $172.36.
View the best growth stocks for 2023 here
.

When is Reata Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RETA earnings forecast
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($2.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.88) by $0.56. The business had revenue of $22.75 million for the quarter, compared to analyst estimates of $0.85 million.

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.76%), Boxer Capital LLC (3.81%), State Street Corp (1.90%), Perceptive Advisors LLC (1.76%), Holocene Advisors LP (1.78%) and Geode Capital Management LLC (1.58%). Insiders that own company stock include Andrea Loewen, Bhaskar Anand, Colin John Meyer, Dawn Carter Bir, Elaine Castellanos, James Warren Huff, Manmeet Singh Soni, Michael D Wortley, Samina Khan and Shamim Ruff.
View institutional ownership trends
.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $172.36.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $6.58 billion and generates $2.22 million in revenue each year.

How many employees does Reata Pharmaceuticals have?

The company employs 321 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.

This page (NASDAQ:RETA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -